Ozempic and Peripheral Neuropathy: What Semaglutide Users in Mankato Should Watch For
- Jun 12
- 9 min read
If you are on a long-term GLP-1 medication and noticing tingling, numbness, or burning in your feet, the early peripheral neuropathy symptoms below are worth reporting to your prescribing provider.
Summary
A growing number of Mankato-area patients on long-term Ozempic, Wegovy, Mounjaro, or Zepbound are noticing early peripheral neuropathy symptoms: tingling in the feet, numbness, burning, balance changes. The GLP-1 medications themselves do not directly damage peripheral nerves. They can, over many months, produce a pattern of micronutrient depletion that peripheral nerves are particularly sensitive to.
The right move when these symptoms appear is not to stop the medication. The right move is to bring the symptoms and a request for a comprehensive workup to your prescribing provider, address any depletion that has developed, and continue the medication with appropriate nutritional support if and when your prescriber agrees. Stenzel Chiropractic Clinic in Mankato sees patients seeking this nutritional and metabolic foundational support in coordination with their prescribing providers.
Important disclaimer. This article is general patient education from a Doctor of Chiropractic. It is not a substitute for evaluation by your prescribing physician, endocrinologist, or neurologist. Do not start, stop, or change the dose of any prescription medication, including Ozempic (semaglutide), Wegovy, Mounjaro (tirzepatide), Zepbound, or any other GLP-1 receptor agonist, based on the contents of a blog post. Any change to a GLP-1 medication must be made with the prescribing provider. If you are experiencing new peripheral neuropathy symptoms, the first call is to your prescribing provider, not to a chiropractor.
The pattern we are seeing in Mankato
Over the last 18 months, our Mankato peripheral neuropathy practice has begun to see a recognizable pattern: patients in their 40s, 50s, and 60s with no prior history of peripheral neuropathy, no diabetes, no chronic alcohol use, no chemotherapy, no autoimmune disease, presenting with early peripheral neuropathy symptoms. Tingling in the feet. Occasional numbness. Nocturnal symptoms. Mild balance changes.
The shared factor: most of these patients have been on a GLP-1 medication for at least 6 to 12 months. Some for type 2 diabetes management. A larger fraction for weight loss, semaglutide as Wegovy or compounded, tirzepatide as Zepbound or compounded.
Few were told by their prescribing provider that peripheral neuropathy could be a long-term consideration. The patient information for the GLP-1 class lists nausea, vomiting, and gastrointestinal side effects prominently. It does not, in most cases, name peripheral neuropathy at all.
This is not a criticism of the prescribers. The mechanism by which GLP-1s appear to produce peripheral neuropathy symptoms is not a direct toxic effect of the drug. It is a downstream consequence of sustained caloric restriction, slowed gastric emptying, and, in patients with frequent nausea, reduced absorption of the micronutrients peripheral nerves require to remain healthy.
Bottom line. GLP-1 medications are not directly toxic to peripheral nerves. The pattern we are describing is general patient education only, not a clinical claim about your particular medication or your particular situation. Any decision about your GLP-1 must be made with your prescribing provider after appropriate evaluation.
The proposed mechanism, in plain language
The GLP-1 medication class acts on multiple physiological systems at once. Three of those effects can matter for peripheral nerve health over time.
Sustained caloric restriction
Patients on GLP-1s commonly reduce daily caloric intake by a quarter to a third or more. For weight loss this is the intended effect. For nutritional status, it becomes a consideration when the reduced intake is also lower in the nutrient-dense foods peripheral nerves require: animal protein, leafy greens, eggs, dairy. A patient eating a substantially reduced calorie load of low-quality processed food can run a sustained deficit in B12, B6, folate, magnesium, iron, and zinc over many months.
Slowed gastric emptying and reduced gastric acid output
GLP-1s delay gastric emptying as part of their satiety mechanism. The trade-off is that the stomach acid environment that liberates B12 from food protein has less time to act, and intrinsic factor output may be reduced in some patients. The B12 deficiency seen in long-term proton pump inhibitor users follows a similar mechanism.
The laboratory pattern we are seeing in some long-term GLP-1 patients with new peripheral neuropathy symptoms: serum B12 may be normal or low-normal. Methylmalonic acid (MMA) is elevated. Homocysteine is elevated. This is the laboratory signature of tissue-level B12 depletion that is missed when only serum B12 is checked. It is general education only. Your prescribing provider will determine what testing is appropriate for your situation.
Reduced food volume and, sometimes, frequent vomiting
For some patients, particularly during dose escalation, nausea and vomiting are sustained. Even when the medication is well tolerated, food volume often drops substantially. The result is the same: less substrate in, less micronutrient absorbed.
Bottom line. The proposed mechanism for GLP-1-associated peripheral neuropathy is multifactorial micronutrient depletion, primarily B12, methylfolate, B6, iron, and magnesium, not direct nerve toxicity. The clinical implications for any individual patient must be assessed by the prescribing provider with appropriate testing.
Early peripheral neuropathy symptoms to report to your prescribing provider
The early symptoms of peripheral neuropathy are subtle. Most of our Mankato patients describe their first symptoms in retrospect. They did not know what to watch for. If you are on a long-term GLP-1, the symptoms below are worth reporting to the provider who is managing your medication:
Tingling, pins and needles, or burning in the feet, especially bilateral, especially at night
Reduced sensation in the toes or balls of the feet
Balance changes, especially in low light
Nighttime calf cramps, often the earliest warning
A buzzing or vibration sensation in the feet that was not there before
Loss of fine motor control in the fingers
None of these symptoms is specific to GLP-1-associated peripheral neuropathy. Each one is worth investigating in any patient, particularly a Mankato patient over 50 on a long-term GLP-1. The investigation belongs with the prescribing provider.
What to ask your prescribing provider in Mankato
If you have been on Ozempic, Wegovy, Mounjaro, or Zepbound for more than six months, and especially if you are noticing any of the peripheral neuropathy symptoms above, these are reasonable questions to bring to your next Mankato-area appointment with the provider who prescribed it:
Have we checked my B12, methylmalonic acid (MMA), and homocysteine, not just serum B12?
Have we checked my folate, ferritin, magnesium, and vitamin D?
Are there nutritional supports you would recommend while I continue the medication?
Should we add any neurological monitoring to my regular visits?
If I develop peripheral neuropathy symptoms, what is the plan?
These questions help frame an evidence-based conversation. They do not replace clinical judgment from your prescribing provider.
Where Stenzel Chiropractic Clinic in Mankato fits in
Stenzel Chiropractic Clinic in Mankato is not a substitute for the prescribing provider who manages your GLP-1 medication. We are a foundational care option for Mankato patients who, in coordination with their prescriber, want to address the metabolic and nutritional foundation that supports peripheral nerve health.
What that typically looks like:
Patient brings their prior labs and prescribing-provider correspondence to a free fifteen-minute Mankato consult
We review the picture, suggest what additional testing the prescribing provider might consider, and explain what foundational nutritional support could look like alongside the medication
The patient takes that information back to the prescribing provider, who decides what is appropriate
Where the prescribing provider agrees, we provide foundational nutritional support, the MitoNAD+ approach, in coordination with the prescription medication
We do not advise patients to stop their GLP-1. We do not adjust prescription medication. We work underneath, with the prescribing provider's awareness, on the nutritional and metabolic foundation peripheral nerves need.
Bottom line. Stenzel Chiropractic Clinic in Mankato works in coordination with, never in place of, the prescribing provider for GLP-1 patients. The medication decisions belong to the prescriber. The foundational nutritional support, where appropriate and approved, is what we offer.
A note on the evidence
To be precise about what this article is and is not claiming: the absolute rate of clinically significant peripheral neuropathy attributable to GLP-1 use is not yet established in the published literature. The pattern described above is what we are seeing in our Mankato practice and is mechanistically consistent with what is known about caloric restriction, gastric emptying, and B12 absorption. Larger-scale published data on this specific consideration will likely emerge over the next several years as the GLP-1 user population accumulates duration of exposure.
What can reasonably be said in 2026: the mechanism is plausible, the depletion pattern is real in some patients we have evaluated, the testing is well-established, and the appropriate response is to coordinate with the prescribing provider, not to stop the medication based on a blog post.
Schedule a free peripheral neuropathy consult in Mankato
If you are on a GLP-1 medication and noticing peripheral neuropathy symptoms, the first call is to your prescribing provider. If you would like a foundational nutritional and metabolic perspective to bring to that appointment, a fifteen-minute consult at our Mankato clinic is free. You leave with general patient education about what testing your prescribing provider might consider and what foundational support could look like, not a treatment recommendation that bypasses your prescriber.
Book now at stenzelchiropractic.janeapp.com. Learn more about our peripheral neuropathy program at stenzelchiropractic.com/neuropathy. Locations: Mankato, MN (1704 N. Riverfront Drive, Suite 101) and Mapleton, MN (313 Main St NE).
Frequently Asked Questions
Can Ozempic cause peripheral neuropathy?
GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro, Zepbound) are not directly toxic to peripheral nerves. They can, over months to years of use, contribute to a pattern of micronutrient depletion, particularly of vitamin B12, methylfolate, B6, iron, and magnesium, that some peripheral nerves are sensitive to. Any peripheral neuropathy symptoms in a GLP-1 user should be reported to the prescribing provider for evaluation. This is general patient education, not a clinical conclusion about any individual patient.
Should I stop Ozempic if I have nerve symptoms?
Do not stop Ozempic, Wegovy, Mounjaro, Zepbound, or any GLP-1 medication based on a blog post or on advice from anyone other than your prescribing provider. New peripheral neuropathy symptoms in a GLP-1 user are a reason to call the prescribing provider, request appropriate testing, and discuss whether nutritional support should be added. The medication's glycemic and weight benefits often can be preserved while nutritional support is added, but that decision belongs to the prescriber.
What testing might my Mankato prescribing provider consider if I am on semaglutide or tirzepatide long-term?
Questions reasonable to bring to a prescribing provider include whether B12, methylmalonic acid (MMA), homocysteine, folate, ferritin and a full iron panel, magnesium, vitamin D, HbA1c, fasting glucose, and fasting insulin have been checked. Serum B12 alone is often insufficient. MMA is generally considered more sensitive for tissue-level deficiency. What testing is appropriate for any individual patient is determined by the prescribing provider.
Does Mounjaro (tirzepatide) or Zepbound carry the same considerations as Ozempic?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. The dual mechanism produces stronger glycemic and weight effects than semaglutide, and stronger gastrointestinal effects in many patients. The proposed micronutrient depletion mechanism is the same and may be more pronounced. Monitoring questions for your prescribing provider are the same.
How long do GLP-1-related peripheral neuropathy symptoms take to improve with nutritional support?
Some patients in our Mankato practice with a depletion-driven picture experience meaningful symptom reduction within six weeks of foundational nutritional restoration, but only when the prescribing provider has agreed to the plan and supervised the medication. Functional measures typically improve at the 60 to 90 day mark. Patients with longer-duration symptoms or compounding factors improve more slowly. Individual results vary.
Where can I get a foundational nutritional consult for GLP-1-related peripheral neuropathy in Mankato?
Stenzel Chiropractic Clinic in Mankato offers a free fifteen-minute consult for people seeking foundational nutritional and metabolic education to bring to their prescribing provider. We do not adjust prescription medication. We do not advise stopping a GLP-1. We work in coordination with, never in place of, the prescribing provider.
Sources
Camilleri M, Acosta A. Combination Therapies for Obesity. Metab Syndr Relat Disord. 2018;16(8):390 to 394.
Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754 to 1761. PMID 26900641.
Smits MM, van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:645563.
Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435 to 2442. PMID 24327038.
Stabler SP. Vitamin B12 Deficiency. N Engl J Med. 2013;368(2):149 to 160. PMID 23301732.
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795 to 1797.
Dr. Jordan Stenzel, DC is a Doctor of Chiropractic practicing in Mankato and Mapleton, Minnesota. Stenzel Chiropractic Clinic focuses on foundational metabolic care for peripheral neuropathy and related chronic conditions. This article is general patient education from a chiropractor. It is not medical advice and not a substitute for evaluation by the physician or provider managing your prescription medication. Do not start, stop, or modify any medication, including GLP-1 receptor agonists, based on the contents of this article. Any change to a prescription medication must be made in coordination with the prescribing provider. Always consult your treating provider first.
Great article. Helpful to know what symptoms to look for, and the science is explained in plain language. Nicely done.